Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ACTI.ST
- Price
- 0.08
- Stock movement up
- +0.00 (2.53%)
- Company name
- Active Biotech AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 94.60M
- Ent værdi
- 101.90M
- Pris/omsætning
- -
- Pris/bog
- 67.57
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -2.77%
- 1 års afkast
- -78.64%
- 3 års afkast
- -
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2025-10-30
UDBYTTE
ACTI.ST betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | - |
| Pris til egenkapital | 67.57 |
| EV i forhold til salg | - |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 1.23B |
| EPS (TTM) | - |
| FCF pr. aktie (TTM) | - |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | - |
| Bruttofortjeneste (TTM) | - |
| Driftsindkomst (TTM) | - |
| Nettoindkomst (TTM) | - |
| EPS (TTM) | - |
| EPS (1 år frem) | - |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenstmargin (TTM) | - |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 6.20M |
| Nettotilgodehavender | 4.40M |
| Omsætningsaktiver i alt | 10.70M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 200.00K |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 14.90M |
| Kreditor | 0.00 |
| Kortfristet/nuværende langsigtet gæld | 0.00 |
| Summen af kortfristede forpligtelser | 11.50M |
| Sum gæld | 13.50M |
| Aktionærernes egenkapital | 1.40M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | - |
| Investeringsudgifter (TTM) | - |
| Fri pengestrøm (TTM) | - |
| Udbetalt udbytte (TTM) | - |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | - |
| Afkast af aktiver | - |
| Afkast af investeret kapital | - |
| Kontant afkast af investeret kapital | - |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 0.08 |
| Daglig høj | 0.08 |
| Daglig lav | 0.07 |
| Daglig volumen | 1.96M |
| Højeste gennem alle tider | 130.62 |
| 1 års analytiker estimat | 0.50 |
| Beta | 1.45 |
| EPS (TTM) | - |
| Udbytte pr. aktie | 0.00 |
| Ex-div dato | 17 Apr 1998 |
| Næste dato for resultatpræsentation | 6 Nov 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACTI.ST | S&P500 | |
| Nuværende prisfald fra top notering | -99.94% | -1.10% |
| Højeste prisfald | -99.95% | -19.00% |
| Højeste efterår dato | 8 Apr 2025 | 8 Apr 2025 |
| Gennemsnitlig fald fra toppen | -99.88% | -2.76% |
| Gennemsnitlig tid til nyt højdepunkt | - | 5 days |
| Maks. tid til nyt højdepunkt | 265 days | 89 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
94.60M
Markedsværdi kategori
Small-cap
Beskrivelse
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvironment which is in phase I/II for the treatment of hematological cancers, such as myelofibrosis and multiple myeloma; and Naptumomab, an immunotherapy, which is in phase Ib/II study to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas ans Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Personale
5
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Sweden
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
The cider brand has added a high-contrast NaviLens QR code to its cans.
9. september 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
9. september 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
9. september 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
9. september 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
9. september 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
9. september 2025